Becton Dickinson to Pay $85 Million to Resolve Claims Over Alaris Infusion Pump
By Sabela Ojea
Becton Dickinson agreed to pay a settlement of $85 million to resolve claims against the company and its officers regarding its Alaris infusion pump.
The medical technology company on Thursday said it filed the settlement documents and it is seeking approval by the U.S. District Court for the District of New Jersey.
The company's results and free cash flow position won't be materially impacted by the settlement, linked to a class action shareholder litigation filed in February 2020.
Investors accused the company of hiding looming regulatory hurdles impacting sales of its Alaris infusion pump.
Becton Dickinson and its management have denied any wrongdoing, the company added.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
December 21, 2023 17:35 ET (22:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing